Early effect of nasal salmon calcitonin on the bone marker Crosslaps
β Scribed by Demet Ofluoglu; Evrim Karadag-Saygi; Cuneyt Canbulat; Osman Hakan Gunduz; Evren KUL-Panza; Gulseren Akyuz
- Publisher
- Springer
- Year
- 2005
- Tongue
- English
- Weight
- 179 KB
- Volume
- 26
- Category
- Article
- ISSN
- 0172-8172
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
In order to devise a convenient and effective therapeutic regimen of intranasal salmon calcitonin (sCT) for the treatment of early postmenopausal bone loss, we studied the effects of a 1-year course of sCT nasal spray on vertebral mineral content (VMC), assessed by dual photon densitometry, and bone
We reviewed data on 42 postmenopausal women with established osteoporosis (forearm fracture or a low bone mass) who had been randomly treated for 1 year with either rectal salmon calcitonin (sCT), 100 IU daily (n = 25) or nasal sCT, 200 IU daily (n = 17) applying an estimation algorithm for bone los
We examine the dose-related effect of intranasal salmon calcitonin (sCT) on the early postmenopausal bone loss and bone turnover; a 2-year, prospective, randomized, double-blind, placebo-controlled study was carried out with 134 healthy women who had passed a natural menopause within 6 months to 3 y